Copy Link Print Information

Dacomitinib hydrate

(Synonyms: PF-00299804 hydrate; PF-299804 hydrate)
29 Cited Publications
Customer Review

Based on 29 publication(s) in Google Scholar

Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC).

For research use only. We do not sell to patients.

  • Purity: 99.54%
  • CAS No.: 1042385-75-0
  • Formula: C24H27ClFN5O3
  • Molecular Weight:487.95
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Dacomitinib hydrate Chemical Structure
    Dacomitinib hydrate Chemical Structure
  • Experimental Validation Results for Dacomitinib hydrate
  • Experimental Validation Results for Dacomitinib hydrate
  • Experimental Validation Results for Dacomitinib hydrate
  • Experimental Validation Results for Dacomitinib hydrate
  • Experimental Validation Results for Dacomitinib hydrate
CAS No.: 1042385-75-0
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Dacomitinib hydrate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Dacomitinib hydrate

More
Customer Validation & Images
Cell Proliferation/Viability AssayWBIn Vivo Efficacy StudyFlow CytometryCell Imaging/Staining
  • In Vivo Efficacy Study
  • Cell Imaging/Staining
  • Cell Proliferation/Viability Assay
  • WB
  • Flow Cytometry

All EGFR Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Dacomitinib hydrate Chemical Structure
    Dacomitinib hydrate Chemical Structure
    1/16
  • 1/16

    Dacomitinib hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 9:e07524. [Abstract]

    Customer Validation
     Dacomitinib (7 mg/kg, i.g.) largely improved the radiosensitivity of subcutaneous xenograft tumors.

  • 1/16

    Dacomitinib hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 9:e07524. [Abstract]

    Customer Validation
     The combination of Dacomitinib (7 mg/kg, i.g.) and IR induced much more cell death than either IR or dacomitinib alone.

  • 1/16

    Dacomitinib hydrate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 19;44(1):245. [Abstract]

    Customer Validation
     Primary gastric cancer (GC-1 and GC-2) cells treated with Pyrotinib, Dacomitinib, Afatinib, or DMSO (control) at 1 µM concentration over 3 days, growth curves represent three independent experiments.

  • 1/16

    Dacomitinib hydrate purchased from MedChemExpress. Usage Cited in: Molecules. 2024 Jan 4;29(1):274. [Abstract]

    Customer Validation
     SKOV3-TR cells were treated with combination of Dacomitinib (0, 0.1, 0.5, and 1 µM) and Paclitaxel (0, 10, 100, and 200 nM) as indicated for 48 h, and then cleaved PARP was analyzed by immunoblotting.

  • 1/16

    Dacomitinib hydrate purchased from MedChemExpress. Usage Cited in: Molecules. 2024 Jan 4;29(1):274. [Abstract]

    Customer Validation
     SKOV3-TR cells were subjected to treatments with DMSO (Mock), 200 nM paclitaxel, 1 µM Dacomitinib, and combination of 200 nM Paclitaxel and 1 µM Dacomitinib each for 48 h. Apoptotic cell death was analyzed by FACS analysis.

  • Dacomitinib hydrate